Tracon Pharmaceuticals Inc (TCON)

$0.03 -0.01 (-25.98%)
Market Cap 110,000.00
Revenue (ttm) 12.05M
Net Income (ttm) -3.59M
EPS (ttm) N/A
PE Ratio 0.01
Forward PE N/A
Profit Margin -29.79%
Debt to Equity Ratio 0.00
Volume 23,800
Avg Vol 13,582
Day's Range N/A - N/A
Shares Out 3.41M
Stochastic %K 14%
Beta 1.37
Analysts Strong Buy
Price Target $6.00

Company Profile

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indicati...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 0780
Fax: 858 550 0786
Address:
4350 La Jolla Village Drive, Suite 800, San Diego, United States
WallStVisions
WallStVisions Sep. 24 at 1:41 PM
XPON has one of the most overlooked setups in small caps: — Lithium + battery exposure — Clean tech focus — Micro float — Chart is curling Volume + news = rapid move potential. Don’t miss it. $RCEL $LYRA $TCON $ARQT $UBX
0 · Reply
hbseth
hbseth Sep. 19 at 2:34 PM
$KAPA originally developed by $TCON Carotuximabs value potential can be calculated by clicking on $TCON
0 · Reply
sirspanky
sirspanky Sep. 3 at 4:01 PM
$HCTI 💡 hasn’t dropped news since the RS & yes it’s been painful… but look closer 👉 scrubbing LinkedIn shows a clear pattern: new hires across brands from June–Aug. While the market sees “silence,” the company is quietly scaling talent across EHR, AI, & consulting. That doesn’t happen by accident. ✅ Q2 only showed 2 weeks of numbers. ✅ Fresh staff = capacity to chase bigger contracts. ✅ Compliance locked. The silence since? Not weakness—LinkedIn shows aggressive hiring June–Aug across AI, EHR, and consulting. That’s execution, not vacuum. Look at history: $SGBX ripped +86% post-split on news. $TCON reset, then pivoted w/ strategic updates. $MRIN used its split as a springboard for growth. Now $HCTI is setting up the same way. 4-hr chart curling, volume base forming. Fundamentals show Q2 was only 2 wks of new rev—Q3 will be the first real look. Quiet build → Loud breakout. Stay ahead of the crowd. This is a classic setup: a company building quietly while investors panic.
2 · Reply
hbseth
hbseth Aug. 23 at 7:47 PM
$KAPA TRACON $TCON originally developed Carotuximab for Sarcoma which didn't do well in trials. However, Kairos emphasizes ENV105’s role in resistance reversal for current Prostate, Lung, Head, Neck, Breast and Colon cancers that have already confirmed good results. Whether this redirection of use is a licensing agreement, buyout or partnership is unclear. Every interview with this CEO hints at partnerships. $TCON was liquidated in 2024 so it would be assumed that $KAPA would be the current licensed holder of Carotuximab (rebranded as ENV105) for Prostate targeted drugs, not Sarcoma. This is why revenue would go directly to Kairos Pharma and current/future partnerships.
1 · Reply
WallStVisions
WallStVisions Jul. 19 at 2:27 AM
RSLS is the quiet kind of setup that blindsides the market. Merger confirmed. Micro float. No dilution cloud. Biotech names like this don’t need hype they just need a headline. By the time it’s trending, the easy money will already be made. $TCON $BIVI $INAB $DRMA
0 · Reply
CatherineLaing1007
CatherineLaing1007 Jun. 11 at 4:15 PM
$TCON saw some early action but AMBR is gaining more consistent visibility.
0 · Reply
AmandaBlakes1061
AmandaBlakes1061 Jun. 6 at 3:10 PM
$TCON is developing treatments while ZBAO is developing serious chart momentum.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 8:28 AM
$TCON Tough break for TCON. Dissolution looks imminent after failed envafolimab trial. Clinical-stage biotech life is brutal - one missed endpoint can tank everything. Might grab some shares if liquidation value looks promising. Watching TRC102 trial closely. compelling article: https://beyondspx.com/article/tracon-pharmaceuticals-tcon-a-unique-biotech-navigating-challenging-waters
0 · Reply
Respectable_Level
Respectable_Level Mar. 24 at 2:36 PM
$TCON RIP
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 28 at 4:28 AM
$TCON TRACON Pharmaceuticals, Inc. (NASDAQ:TCON): Leveraging Innovative Clinical Development Platform to Advance Oncology Pipeline https://beyondspx.com/article/tracon-pharmaceuticals-inc-nasdaq-tcon-leveraging-innovative-clinical-development-platform-to-advance-oncology-pipeline
0 · Reply
Latest News on TCON
No data available.
WallStVisions
WallStVisions Sep. 24 at 1:41 PM
XPON has one of the most overlooked setups in small caps: — Lithium + battery exposure — Clean tech focus — Micro float — Chart is curling Volume + news = rapid move potential. Don’t miss it. $RCEL $LYRA $TCON $ARQT $UBX
0 · Reply
hbseth
hbseth Sep. 19 at 2:34 PM
$KAPA originally developed by $TCON Carotuximabs value potential can be calculated by clicking on $TCON
0 · Reply
sirspanky
sirspanky Sep. 3 at 4:01 PM
$HCTI 💡 hasn’t dropped news since the RS & yes it’s been painful… but look closer 👉 scrubbing LinkedIn shows a clear pattern: new hires across brands from June–Aug. While the market sees “silence,” the company is quietly scaling talent across EHR, AI, & consulting. That doesn’t happen by accident. ✅ Q2 only showed 2 weeks of numbers. ✅ Fresh staff = capacity to chase bigger contracts. ✅ Compliance locked. The silence since? Not weakness—LinkedIn shows aggressive hiring June–Aug across AI, EHR, and consulting. That’s execution, not vacuum. Look at history: $SGBX ripped +86% post-split on news. $TCON reset, then pivoted w/ strategic updates. $MRIN used its split as a springboard for growth. Now $HCTI is setting up the same way. 4-hr chart curling, volume base forming. Fundamentals show Q2 was only 2 wks of new rev—Q3 will be the first real look. Quiet build → Loud breakout. Stay ahead of the crowd. This is a classic setup: a company building quietly while investors panic.
2 · Reply
hbseth
hbseth Aug. 23 at 7:47 PM
$KAPA TRACON $TCON originally developed Carotuximab for Sarcoma which didn't do well in trials. However, Kairos emphasizes ENV105’s role in resistance reversal for current Prostate, Lung, Head, Neck, Breast and Colon cancers that have already confirmed good results. Whether this redirection of use is a licensing agreement, buyout or partnership is unclear. Every interview with this CEO hints at partnerships. $TCON was liquidated in 2024 so it would be assumed that $KAPA would be the current licensed holder of Carotuximab (rebranded as ENV105) for Prostate targeted drugs, not Sarcoma. This is why revenue would go directly to Kairos Pharma and current/future partnerships.
1 · Reply
WallStVisions
WallStVisions Jul. 19 at 2:27 AM
RSLS is the quiet kind of setup that blindsides the market. Merger confirmed. Micro float. No dilution cloud. Biotech names like this don’t need hype they just need a headline. By the time it’s trending, the easy money will already be made. $TCON $BIVI $INAB $DRMA
0 · Reply
CatherineLaing1007
CatherineLaing1007 Jun. 11 at 4:15 PM
$TCON saw some early action but AMBR is gaining more consistent visibility.
0 · Reply
AmandaBlakes1061
AmandaBlakes1061 Jun. 6 at 3:10 PM
$TCON is developing treatments while ZBAO is developing serious chart momentum.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 8:28 AM
$TCON Tough break for TCON. Dissolution looks imminent after failed envafolimab trial. Clinical-stage biotech life is brutal - one missed endpoint can tank everything. Might grab some shares if liquidation value looks promising. Watching TRC102 trial closely. compelling article: https://beyondspx.com/article/tracon-pharmaceuticals-tcon-a-unique-biotech-navigating-challenging-waters
0 · Reply
Respectable_Level
Respectable_Level Mar. 24 at 2:36 PM
$TCON RIP
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 28 at 4:28 AM
$TCON TRACON Pharmaceuticals, Inc. (NASDAQ:TCON): Leveraging Innovative Clinical Development Platform to Advance Oncology Pipeline https://beyondspx.com/article/tracon-pharmaceuticals-inc-nasdaq-tcon-leveraging-innovative-clinical-development-platform-to-advance-oncology-pipeline
0 · Reply
mako77
mako77 Dec. 31 at 12:33 PM
$TCON https://www.globenewswire.com/news-release/2024/04/03/2856880/10391/en/TRACON-Pharmaceuticals-Provides-Update-on-Ongoing-ENVASARC-Phase-2-Pivotal-Trial-Following-Independent-Data-Monitoring-Committee-Recommendation-to-Continue-the-Trial-as-Planned.html
0 · Reply
Wookdo
Wookdo Dec. 21 at 3:10 AM
$TCON Is anyone here?
0 · Reply
ieatbaguette
ieatbaguette Nov. 1 at 5:40 PM
$TCON taoping next t a O p
0 · Reply
bas575
bas575 Oct. 16 at 1:46 AM
$HALO What are they thinking hiring Charles Theuer as CMO? Do they know what this guy (leaving out the unsavory expletives) did to $TCON? He flattened wallets and more...and did very well out of it.
1 · Reply
Respectable_Level
Respectable_Level Oct. 5 at 3:18 PM
$TCON What happened here? I’m late to the news. Sold this long time ago. Shit leadership is to blame.
0 · Reply
MuesLee
MuesLee Sep. 17 at 9:06 PM
$TCON CRAZY moves ... Why?
0 · Reply
PRGuiney
PRGuiney Aug. 30 at 4:37 PM
$TCON any reason to keep this or is it time to take the loss? I wouldn’t mind holding it until 2025 to take the loss for the new tax year but not sure this piece of junk will survive that long?
2 · Reply
bas575
bas575 Aug. 13 at 10:54 PM
$TCON After creaming stockholders for millions over the years, Charles walks away one more freeloading time with a sweet severance deal - and it would seem, gets away with it. That bullshitter has got a lot of gall looking for a consulting gig in the bio space. If anyone pays him as a consultant, I would be highly suspicious of their motives. 🤷‍♂️
1 · Reply